Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CASP6 | P55212 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24109185 | 0.81 | MEN1 (0.31) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL26482155 | 0.77 | HPGDS (0.30) | — | |
| SCHEMBL7921131 | 0.75 | RAB9A (0.42) | NOS1NOS2CCR1RAB9ACCR5 | |
| SCHEMBL15935225 | 0.72 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL18469476 | 0.67 | ALDH1A1 (0.44) | NOS1CYP1A2MEN1KMT2AL3MBTL1 | |
| SCHEMBL16479973 | 0.67 | MEN1 (0.35) | MEN1KMT2AL3MBTL1ALDH1A1TSHR | |
| SCHEMBL30062368 | 0.66 | PARP1 (0.42) | NOS1NOS2RAB9ACYP1A2LMNA | |
| SCHEMBL3860414 | 0.65 | NOS1 (0.48) | NOS1NOS2CCR1RAB9ACCR5 | |
| SCHEMBL14788303 | 0.65 | MEN1 (0.39) | MEN1KMT2AL3MBTL1ALDH1A1TSHR | |
| SCHEMBL25054165 | 0.64 | CYP1A2 (0.38) | CYP1A2MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322744-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | NOS1 3565/4885NOS2 4265/4885CCR1 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.